Entera Bio (Nasdaq:ENTX) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ENTX Stoklara Genel Bakış

ENTX temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Earnings have grown 2.3% per year over the past 5 years

Risk Analizi

Earnings are forecast to decline by an average of 89.7% per year for the next 3 years

Makes less than USD$1m in revenue ($57K)

Does not have a meaningful market cap ($69M)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 daha fazla risk

Entera Bio Ltd. Rakipler

RAPT Therapeutics

NasdaqGM:RAPT

US$70.2m

Immuneering

NasdaqGM:IMRX

US$73.8m

vTv Therapeutics

NasdaqCM:VTVT

US$40.8m

Cibus

NasdaqCM:CBUS

US$93.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Entera Bio
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.83
52 Haftanın En Yüksek Seviyesi	US$3.35
52 Haftanın En Düşük Seviyesi	US$0.52
Beta	1.58
11 Aylık Değişim	9.58%
3 Aylık Değişim	11.59%
1 Yıllık Değişim	154.17%
33 Yıllık Değişim	-60.04%
5 Yıllık Değişim	-18.67%
Halka arzdan bu yana değişim	-70.86%

Son Haberler & Güncellemeler

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Jul 12

Recent updates

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Jul 12

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Mar 23

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Oct 06

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Jun 19

Entera Bio secures European patent for oral PTH formulations

Jun 17

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Mar 20

Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely

Dec 05

Entera Bio EPS misses by $0.22

Nov 19

Hissedar Getirileri

	ENTX	US Biotechs	US Pazar
7D	-6.6%	-0.2%	-0.4%
1Y	154.2%	22.1%	34.1%

Getiri vs. Endüstri: ENTX exceeded the US Biotechs industry which returned 21.7% over the past year.

Getiri vs Piyasa: ENTX exceeded the US Market which returned 33.4% over the past year.

Fiyat Oynaklığı

Is ENTX's price volatile compared to industry and market?
ENTX volatility
ENTX Average Weekly Movement	10.6%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ENTX has not had significant price volatility in the past 3 months.

Zaman İçindeki Volatilite: ENTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	18	Miranda Toledano	www.enterabio.com

Klinik aşamada bir şirket olan Entera Bio Ltd., oral tablet formunun bakım standardını dönüştürme potansiyeline sahip olduğu karşılanmamış tıbbi ihtiyaçlar için oral peptit veya protein replasman tedavileri geliştirmeye odaklanmaktadır. Şirket, peptidi gastrointestinal sistemde aynı anda stabilize etmek ve kan dolaşımına emilimini teşvik etmek için tasarlanmış bir oral dağıtım teknolojisi olan N-Tab'den yararlanmaktadır. Gelişmiş ürün adayı EB613 (oral PTH (1-34)), düşük kemik mineral yoğunluğu ve yüksek riskli osteoporozu olan menopoz sonrası kadınlar için ilk oral, osteoanabolik (kemik yapıcı) günde bir kez tablet tedavisi olarak Faz 3 geliştirmeye girmektedir.

Entera Bio Ltd. Temel Bilgiler Özeti

Entera Bio'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ENTX temel i̇stati̇sti̇kler
Piyasa değeri	US$69.02m
Kazançlar(TTM)	-US$8.54m
Gelir(TTM)	US$57.00k

1,166x

P/S Oranı

-7.8x

F/K Oranı

ENTX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ENTX gelir tablosu (TTM)
Gelir	US$57.00k
Gelir Maliyeti	US$48.00k
Brüt Kâr	US$9.00k
Diğer Giderler	US$8.55m
Kazançlar	-US$8.54m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.23
Brüt Marj	15.79%
Net Kâr Marjı	-14,975.44%
Borç/Özkaynak Oranı	0%

ENTX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ENTX Stoklara Genel Bakış

Ödüller

Risk Analizi

Entera Bio Ltd. Rakipler

NasdaqGM:RAPT

US$70.2m

NasdaqGM:IMRX

US$73.8m

NasdaqCM:VTVT

US$40.8m

NasdaqCM:CBUS

US$93.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New minor risk - Share price stability

Entera Bio Ltd. Announces New Comparative Pharmacological Data for its Investigational Agent EB613 Vs. Forteo® Selected for Presentation at ASBMR

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Insufficient new directors

Entera Bio Ltd., Annual General Meeting, Jul 31, 2024

Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Recent updates

New minor risk - Share price stability

Entera Bio Ltd. Announces New Comparative Pharmacological Data for its Investigational Agent EB613 Vs. Forteo® Selected for Presentation at ASBMR

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Insufficient new directors

Entera Bio Ltd., Annual General Meeting, Jul 31, 2024

Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New minor risk - Shareholder dilution

Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Third quarter 2023 earnings released: US$0.083 loss per share (vs US$0.11 loss in 3Q 2022)

Entera Bio Ltd. Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program

Entera Bio Ltd. Reports Rapid Pharmacodynamic (Pd) Response and Consistent Pharmacokinetic (Pk) Data for Its First-In-Class Oral Pth(1-34) Mini Tablets At the Asbmr 2023 Annual Meeting

New minor risk - Share price stability

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Entera Bio Ltd., Annual General Meeting, Sep 13, 2023

First half 2023 earnings released: US$0.16 loss per share (vs US$0.24 loss in 1H 2022)

Entera Bio Ltd Adds Haya Taitel to its Board of Directors

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Consensus revenue estimates decrease by 97%, EPS upgraded

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022)

Entera Bio Ltd.'S Oral Delivery of GLP-2 Pre-Clinical Data to Be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

No longer forecast to breakeven

Entera Bio Ltd. Announces U.S. Food and Drug Administration Acceptance of Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Price target decreased by 11% to US$6.00

Entera Bio Receives A Notice from Nasdaq Regarding Minimum Bid Price Requirement

Consensus revenue estimates increase by 59%

Price target increased to US$9.50

Insufficient new directors

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Entera Bio Ltd. Announces Fda Agreement for A Single Phase 3 Clinical Trial to Support an NDA for Eb613 for the Treatment of Osteoporosis

Entera Bio Ltd. Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

Price target increased to US$7.50

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M

Insufficient new directors

Entera Bio Ltd., Annual General Meeting, Sep 07, 2022

Entera Bio Ltd. Announces Executive Changes

Insufficient new directors

Entera Bio Ltd. Announces Departure of Dr. Phillip Schwartz, President of Research & Development to Pursue Outside Opportunities

We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Consensus forecasts updated

Entera Bio Ltd. Announces Appointment of Miranda Toledano as Chief Business Officer and Head of Corporate Strategy

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$6.75

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Entera Bio Ltd. Provides Earnings Guidance for the Year Ending December 31, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Entera Bio Ltd. to Report Fiscal Year 2021 Results on Mar 08, 2022